Colorado Prevention Center

This phase 3 trial investigates whether starting a combination of finerenone and empagliflozin early during a hospital stay for heart failure can improve outcomes compared to usual care. About 1,500 adults hospitalized with heart failure will be enrolled. The study measures effec…

This phase 3 trial tests whether finerenone, a non-steroidal mineralocorticoid receptor antagonist, can reduce cardiovascular death and heart failure events in patients with heart failure and reduced ejection fraction who cannot tolerate or are not eligible for standard steroidal…

This study tests whether the drug finerenone can reduce hospitalizations and deaths in people with a certain type of heart failure (with preserved or mildly reduced pumping ability). About 5,200 adults who are currently or recently hospitalized for heart failure will receive eith…

This study tests whether a team of healthcare professionals using a special algorithm can lower 'bad' cholesterol (LDL-C) more effectively than standard care in people with heart or blood vessel disease. About 100 adults with high cholesterol and known vascular disease will be ra…